Skip to main content
. Author manuscript; available in PMC: 2015 Apr 1.
Published in final edited form as: Matrix Biol. 2014 Jan 28;35:143–151. doi: 10.1016/j.matbio.2014.01.010

Fig. 2. Biglycan-mediated increases serum TNF-α and renal dysfunction in TLR-2- and TLR-4-dependent manner.

Fig. 2

(A) Upper panel: Western blot for biglycan protein core after semi purification from plasma of wild type or Tlr2−/−;Tlr4−/− mice that underwent 30 h post-ischemia reperfusion in absence (IRI) or presence of biglycan overexpression (hBGN IRI). Sham operation (Co) or biglycan overexpression alone (hBGN) served as control. Recombinant biglycan protein core (0.3 μg) was used as standard (St). Lower panel: Quantification of serum biglycan concentrations given as fold induction over control mice. Data represent means ± SD of n = 3 experiments. (B, C) ELISA for TNF-α (B) and creatinine (C) from serum of wild type or Tlr2−/−;Tlr4−/− mice treated as in (A). Data represent means ± SD of n = 6 experiments. * p < 0.05. Asterisks indicate significance between defined groups; asterisks above bars indicate significance versus respective control.